Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab versus PVd or Kd in relapsed or refractory multiple myeloma
2023-503444-13-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised trial of teclistamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: progression-free survival. Planned start Mar 2023; status: authorised.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-503444-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503444-13-00.